This study is evaluating the safety and immune response generated by an investigational bivalent COVID-19 vaccine as a primary 3-dose series plus booster in healthy infants and children under 5 who have not previously been vaccinated for COVID-19.
Worldwide, ATRIAL FIBRILLATION is one of the most common causes of stroke. Researchers are now exploring the use of an investigational drug in patients with atrial fibrillation.
The SURMOUNT-MMO Study is evaluating the effectiveness of an investigational medication (trial treatment) on reducing health risks that are commonly found in people who are living with obesity or are overweight. This clinical trial is focusing particularly on cardiovascular (heart) disease and other heart health risks.
If you care for someone who may have a diagnosis of Alzheimer’s disease and they have been experiencing symptoms of disruptive behavior which have made caring for them even more difficult, the ADVANCE-2 study may be an option.
Participation in a clinical trial is 100% voluntary and at your discretion. There is no cost to participate and you may be compensated for study related travel. Investigational medications will be provided at no cost.
You may qualify if you have a type of heart failure where your heart has less strength than normal to pump blood to your body, and if you have not recently been hospitalized for your heart failure or experienced a worsening of your heart failure that required urgent treatment.
Do you or someone you love have symptoms of early Alzheimer’s disease? If you or someone you love is increasingly becoming forgetful, experience difficulties in planning and problems solving, or gets lost in familiar places, these could be signs of early Alzheimer’s disease.
Indago delivers community-based services for Miami and neighboring areas, driving advances in investigational research for new and improved drugs.
Working Hours
Monday-Friday 8:00 AM – 5:00 PM
Saturday (open if necessary)
Sunday (open if necessary)